| 规格: | 98% |
| 分子量: | 377.4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
Background:
ELOVL1-22 is an inhibitor of ELOVL fatty acid elongase 1 (ELOVL1).1It reduces lysohexacosanoylphosphatidylcholine (LPC(C26:0)) synthesis in HEK293 cells (IC50= 400 pM), a marker of ELOVL1 inhibition, and is selective for ELOVL1 over ELOVL4, -6, and -7 (IC50s = >50 µM for all), as well as a panel of 34 receptors at 10 µM. ELOVL1-22 (1-32 mg/kg) reduces blood and CNS levels of LPC(C26:0) in anAbcd1-/-mouse model of adrenoleukodystrophy (ALD), a neurodegenerative disease characterized by rapid inflammatory demyelination of the CNS.
1.Boyd, M.J., Collier, P.N., Clark, M.P., et al.Discovery of novel, orally bioavailable pyrimidine ether-based inhibitors of ELOVL1J. Med. Chem.64(24)17777-17794(2021)
m.cnreagent.com